Moderna (MRNA): Officer filed to sell ~$4.69M
Mock James M, Officer at Moderna, filed to sell ~$4.69M of Moderna shares.
- ~$4.69M
- planned to sell · 35K shares, around Sep 10, 2026
- Planned for
- Sep 10, 2026
- Notice filed
- Sep 10, 2026
What stands out in this filing
- The planned sale is less than 0.01% of the company's shares outstanding.
- How the shares were acquired, per the notice: Restricted Stock Vesting.
- The notice says the shares were received as pay (stock awards or options).
- Broker named on the notice: Fidelity Brokerage Services LLC.
- A Form 144 announces a sale; the Form 4 that follows shows whether it took place, at what price.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Jul 15, 2026InsiderOfficer sold ~$3.61M of MRNA shares in the open market
- Jul 24, 20265% stakeBAILLIE GIFFORD & CO reported a passive stake (13G) of 4.6%
- Jul 31, 2026Company filing · Form 8-K · ResultsReported its results
- Aug 5, 2026Insider · 1 personInsiders: 4 sales (~$28.7M)
- Aug 6, 20265% stakeFMR LLC reported a passive stake (13G) of 13.1%
- Aug 12, 20265% stakeCapital World Investors reported a passive stake (13G) of 5.6%
- Aug 19, 2026Congress · 1 personMembers of Congress: 1 purchase, 1 sale
- Aug 27, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)
- Sep 1, 2026InsiderOfficer sold ~$486K of MRNA shares in the open market
- Sep 10, 2026Insider · 1 personInsiders: 2 sales (~$4.7M)
What came next
- Sep 14, 2026InsiderOfficer sold ~$5.81M of MRNA shares in the open market
- Sep 15, 2026InsiderOfficer sold ~$5.88M of MRNA shares in the open market
- Sep 24, 2026CongressDisclosed partial sale of MRNA — reported range $1,001 - $15,000
- Sep 30, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On September 30, 2026, Moderna, Inc. (“Moderna” or the “Company”) announced the appointment of Juan Andres as its Chief Operating Officer (“COO”) effective October 5, 2026.”
- Oct 14, 2026Insider · 1 personInsiders: 2 sales (~$8.4M)
- Oct 15, 2026InsiderOfficer sold ~$8.64M of MRNA shares in the open market
- Oct 20, 2026CongressDisclosed purchase of MRNA — reported range $1,001 - $15,000
- Nov 5, 20265% stakeFMR LLC reported a passive stake (13G) of 14.8%
- Nov 6, 2026Company filing · Form 8-K · ResultsReported its results
- Nov 13, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 13, 2026 , Moderna, Inc. (the “Company”) entered into a Transitional Services and Retirement Agreement (the “Retirement Agreement”) with Shannon Thyme Klinger, the Company’s Chief Legal Officer, that sets forth the terms of Ms. Klinger’s retirement from the Company.”
- Nov 16, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
- Nov 16, 2026InsiderOfficer sold ~$8.6M of MRNA shares in the open market
- Nov 17, 2026Insider · 1 personInsiders: 3 sales (~$8.3M)
How to read SEC Form 144
Form 144 is a notice that a company insider plans to sell shares. It is filed when the sell order is placed, so it announces a planned sale and does not prove that the sale took place.
Full guide: What is an SEC Form 144?
What else is on file for Moderna
For Moderna, OQRO holds 19 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MRNA page.
How this filing works
Explore the data
Common questions
Which Moderna (MRNA) insider traded, and how much?
Mock James M, Officer at Moderna, filed to sell ~$4.69M of Moderna shares. 35K shares, Form 144 notice of a planned sale.
When did it happen, and when was it made public?
Planned for: Sep 10, 2026. Notice filed: Sep 10, 2026.
What stands out in this filing?
The planned sale is less than 0.01% of the company's shares outstanding. How the shares were acquired, per the notice: Restricted Stock Vesting. The notice says the shares were received as pay (stock awards or options).
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 144, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Moderna recently?
For Moderna, OQRO holds 19 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the MRNA page.
Does this mean MRNA stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Moderna
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 144Nov 17, 2026
- SEC Form 13F-HRNov 16, 2026
Everything OQRO holds on this company is on its MRNA page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
